WO2014053502A1 - A method for predicting the risk of getting cancer or diagnosing cancer in a female subject - Google Patents
A method for predicting the risk of getting cancer or diagnosing cancer in a female subject Download PDFInfo
- Publication number
- WO2014053502A1 WO2014053502A1 PCT/EP2013/070471 EP2013070471W WO2014053502A1 WO 2014053502 A1 WO2014053502 A1 WO 2014053502A1 EP 2013070471 W EP2013070471 W EP 2013070471W WO 2014053502 A1 WO2014053502 A1 WO 2014053502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- pro
- enkephalin
- risk
- female subject
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Definitions
- Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising:
- PENK Pro-Enkepha!in
- Met-Enkephalin a 5 amino acid peptide derived from the Enkephalin precursor (PreProEnkephalin), also named "Opioid Growth Factor” (OGF) is released together with ProEnkephalin-fragments.
- the mature peptide binds to different opioid receptors (Koneru et al, 2009).
- Enkephalin (OGF) was found to have a number of physiological functions. In the CNS it down regulates Substance P associated pain signalling, it plays roles as cytokine (Plotnikoff et al, 1997).
- Proenkephalin related peptides exhibiting antibiotic actions (Goumon et al, 1998).
- Proenkephalin and Enkephalin exhibits anti tumor action and acting as pro-apoptotic agents (Tavish et al , 2007, Donahue et a ., 201 1, Zagon et al , 2009).
- vasoactive peptides for prediction of cancer risks in males has been reported by Belting et al, Cancer, Epidemiology, Biomarkes & Prevention.
- MR-pro-ANP, MR-pro-ADM and copeptin was measured in the fasting plasma from participants of the Malmo Diet and Cancer Study that were free from cancer prior to the baseline exam in 1991 to 1994 (1768 males and 2293 females). The authors stated that among females, there was no relationship between biomarkers and cancer incidence.
- a subject of the present invention was to investigate the prognostic and diagnostic power of PENK for the prediction of cancer incidence and the prediction of the risk of reoccurrence of cancer.
- stable fragments of Pro -Enkephalin (Ernst et al, 2006) in fasting plasma were measured in said Swedish prospective cohort study (Malmo Diet and Cancer Study) and related baseline level of this biomarker to breast-cancer incidence during 15 years of follow- up.
- Pro-Enkephalin is a powerful and highly significant biomarker for woman for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject.
- subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising:
- cancers may be selected from the group comprising breast cancer, lung cancer, pancreatic cancer and colon cancer.
- fragments of Pro-Enkephalin also include Leu-Enkephalin and Met-Enkephalin.
- said cancer is breast cancer. In another specific embodiment of the invention said cancer is l ung cancer.
- subject matter of the present invention is the determination of susceptibility of a woman to aquire cancer, e.g. breast cancer, lung cancer etc
- Data obtained in the present study revealed also a correlation between the risk of getting cancer in male subjects with the level of Pro-Enkephalin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said male subject; this correlation however, was not that statistically significant for the present data set although there was a clear trend for an increased cancer risk at reduced levels of PENK also in males.
- the method according to the invention also for male subjects but in the present study the observed effect was not as strong for males as compared to females. This may be primarily due to the low number of cancer incidents in the male population.
- subject refers to a living human or non-human organism.
- the subject is a human subject.
- a bodily fluid may be selected from the group comprising blood, serum, plasma, urine, cerebro spinal liquid (csf), and saliva.
- said female subject has never had a diagnosed cancer at the time the sample of bodily fluid is taken from said female subject.
- said female subject has been diagnosed before with having cancer and has been cured at the time the sample of bodily fluid is taken from said female subject and the risk of reoccurrence of getting cancer is determined or alternatively the re-occurrence of cancer is predicted.
- Pro-Enkephalin has the following sequence: SEQ ID NO. 1 (Pro-Enkephalin (1-243)
- Fragments of Pro-Enkephalin that may be determined in a bodily fluid may be e.g. selected from the group of the following fragments:
- SEQ ID NO. 6 (Pro Enkephalin 119-159, Mid regional Pro-Enkephalin-fragment, MRPEN )
- Determining the level of Pro-Enkephalin including Leu-Enkephalin and Met-Enkephalin or fragments thereof may mean that the immunoreactivity towards Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin is determined.
- a binder used for determination of Pro-Enkephalin including Leu-Enkephalin and Met-Enkephalin or fragments thereof depending of the region of binding may bind to more than one of the above displayed molecules. This is clear to a person skilled in the art.
- the level of immunoreactive analyte by using at least one binder that binds to a region within the amino acid sequence of any of the above peptide and peptide fragments, is determined in a bodily fluid obtained from said subject; and correlated to the specific embodiments of clinical relevance.
- a binder that binds to a region within the amino acid sequence of any of the above peptide and peptide fragments i.e. Pro-Enkephalin (PENK) and fragments according to any of the sequences 1 to 12
- the level of MPvPEN is determined (SEQ ID NO. 6: Pro-Enkephalin 1 19-159, Mid regional Pro- Enkephalin-fragment, MRPEN ).
- the level of immunoreactive analyte by using at least one binder that binds to MR-PENK is determined and is correlated to the specific embodiments of clinical relevance according to the invention.
- Determining the level of Pro- Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin or fragments thereof may mean that the immunoreactivity towards Pro- Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin is determined.
- a binder used for determination of Pro-Enkephalin including Leu-Enkephalin and Met- Enkephalin or fragments thereof depending of the region of binding may bind to more than one of the above displayed molecules. This is clear to a person skilled in the art.
- the fragment is not Leu-Enkephalin or Met-Enkephalin
- the immunoreactivity towards Pro-Enkephalin or fragments thereof not including Leu-Enkephalin and Met-Enkephalin is determined.
- the level of MRPENK. (SEQ ID NO. 6 (Pro Enkephalin 119-159, Mid regional Pro-Enkephalin-fragment, MRPEN , DAEEDDSLANSSDLLKELLETGDNRERSHHQDGSDNEEEVS) is determined.
- the level of any of the above analytes may be determined by other analytical methods e.g. mass spectroscopy.
- the level of Pro-Enkephalin or fragments thereof are measured with an immunoassay using antibodies or fragments of antibodies binding to Pro-Enkephalin or fragments thereof.
- An immunoassay that may be useful for determining the level of Pro- Enkephalin or fragments thereof of at least 5 amino acids may comprise the steps as outlined in Example 2. All thresholds and values have to be seen in correlation to the test and the calibration used according to Example 2. A person skilled in the art may know that the absolute value of a threshold might be influenced by the calibration used. This means that all values and thresholds given herein are to be understood in context of the calibration used in herein (Example 2).
- the diagnostic binder to Pro-Enkephalin is selected from the group consisting of antibodies e.g. IgG, a typical full-length immunoglobulin, or antibody fragments containing at least the F-variable domain of heavy and/or light chain as e.g. chemically coupled antibodies (fragment antigen binding) including but not limited to Fab-fragments including Fab minibodies, single chain Fab antibody, monovalent Fab antibody with epitope tags, e.g. Fab- V5Sx2; bivalent Fab (mini-antibody) dimerized with the CH3 domain; bivalent Fab or multivalent Fab, e.g. formed via multimerization with the aid of a heterologous domain, e.g.
- antibodies e.g. IgG, a typical full-length immunoglobulin, or antibody fragments containing at least the F-variable domain of heavy and/or light chain as e.g. chemically coupled antibodies (fragment antigen binding) including but not limited to Fab-fragments including
- dHLX domains e.g. Fab-dHLX-FSx2; F(ab')2-fragments, scFv-fragments, multimerized multivalent or/and multispecific scFv- fragments, bivalent and/or bispecific diabodies, BITE® (bispecific T-cell engager), trifunctional antibodies, polyvalent antibodies, e.g. from a different class than G; single-domain antibodies, e.g.
- nanobodies derived from camelid or fish immunoglobulines In a specific embodiment the level of Pro-Enkephalin or fragments thereof are measured with an assay using binders selected from the group comprising aptamers, non-Ig scaffolds as described in greater detail below binding to Pro-Enkephalin or fragments thereof.
- Binder that may be used for determining the level of Pro-Enkephalin or fragments thereof exhibit an affinity constant to Pro-Enkephalin of at least 10 7 M “! , preferred 10 8 M “1 , preferred affinity constant is greater than 10 9 M “1 , most preferred greater than 10 10 M “1 .
- Binding affinity may be determined using the Biacore method, offered as service analysis e.g. at Biaffin, Kassel, Germany (http://www.biaffm.com/de/).
- a human Pro-Enkephalin-control sample is available by ICI-Diagnostics, Berlin, Germany http://www.ici-diagnostics.com/.
- the assay may also be calibrated by synthetic (for our experiments we used synthetic MRPENK, SEQ ID NO. 6) or recombinant Pro-Enkephalin or fragments thereof.
- the threshold for determining the risk of getting breast cancer in a female subject or diagnosing breast cancer in a female subject according to the methods of the present invention is below 100 pmol/1 PENK, preferred below 50 pmol/1, more preferred below 40,4 pmol/1. In a specific embodiment said threshold is about 40,4 pmol/1. These thresholds are related to the above mentioned calibration method.
- a PENK value below said threshold means that the subject has an enhanced risk of getting cancer or has already cancer.
- said method is performed more than once in order to monitor the risk of getting breast cancer in a female subject or in order to monitor the course of treatment. In one specific embodiment said monitoring is performed in order to evaluate the response of said female subject to preventive and/or therapeutic measures taken.
- the method is used in order to stratify said female subjects into risk groups.
- Subject of the present invention is also a method for predicting the risk of getting cancer in a female or identifying a female subject having an enhanced risk for getting cancer according to any of the preceding embodiments, wherein the level of Pro-Enkephalin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject either alone or in conjunction with other prognosticaily useful laboratory or clinical parameters is used for the prediction of a subject's risk for getting an adverse event by a method which may be selected from the following alternatives:
- subject of the present invention is also a method for predicting the risk of getting cancer in a female or identifying a female subject having an enhanced risk for getting cancer according to any of the preceding embodiments, wherein the level of Pro-Enkephalin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject either alone or in conjunction with other prognosticaily useful biomarker.
- a useful biomarker may be Pro-Neurotensin and fragments thereof of at least 5 amino acids.
- the level of Pro- Neurotensin 1-1 17 is determined in addition to the determination of Pro-Enkephalin an fragments thereof.
- subject matter of the present invention is also a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: • determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and
- SEQ ID NO. 14 Pro-Neurotensin 1-125 (large neuromedin N)
- SEQ ID NO. 16 (neurotensin) pyroQLYENKPRRP YIL
- SEQ ID NO. 17 (Pro-Neurotensin 1-117) SDSEEEMKAL EADFLTNMHT SKISKAHVPS WKMTLLNVCS LVNNLNSPAE ETGEVHEEEL VARRKLPTAL DGFSLEAMLT lYQLHKICHS RAFQHWELIQ EDILDTGNDK NGKEEVI
- SEQ ID NO. 18 (Pro-Neurotensin 1 -132)
- SEQ ID NO. 21 (Pro-Neurotensin 128-147)
- the level of Pro-Neurotensin is measured with an immunoassay. More specifically an immunoassay is used as described in Ernst et al. (Peptides (2006), (27) 1787- 1793). An immunoassay that may be useful for determining the level of Pro-Neurotensin or fragments thereof of at least 5 amino acids may comprise the steps as outlined in Example 2. All thresholds and values have to be seen in correlation to the test and the calibration used according to Example 2, A person skilled in the art may know that the absolute value of a threshold might be influenced by the calibration used. This means that all values and thresholds given herein are to be understood in context of the calibration used in herein (Example 2).
- a human Pro- Neurotensin-calibrator is available by ICI-Diagnostics, Berlin, Germany.
- the assay may also be calibrated by synthetic or recombinant P ⁇ NT 1-117 or fragments thereof (see also Ernst et al, 2006).
- Binder that may be used for determining the level of Pro-Neurotensin or fragments thereof exhibit an affinity constant to Pro-Neurotensin of at least 10 7 M "1 , preferred 10 s M “1 , preferred affinity constant is greater than 10 9 M "1 , most preferred greater than 10 10 M ⁇ ⁇ A person skilled in the art knows that it may be considered to compensate lower affinity by applying a higher dose of compounds and this measure would not lead out-of-the-scope of the invention. Binding affinity may be determined using the Biacore method, offered as service analysis e.g.
- the threshold for deteimining the risk of getting breast cancer in a female subject or diagnosing breast cancer in a female subject according to the methods of the present invention is above 78 pmol/1 PNT, preferred 100 pmol/1, more preferred 150 pmol/1. In a specific embodiment said threshold is about 100 pmol/1. These thresholds are related to the above mentioned calibration method. A P-NT value above said threshold means that the subject has an enhanced risk of getting cancer or has already cancer.
- said method is performed more than once in order to monitor the risk of getting breast cancer in a female subject or in order to monitor the course of treatment. In one specific embodiment said monitoring is performed in order to evaluate the response of said female subject to preventive and/or therapeutic measures taken.
- the method is used in order to stratify said female subjects into risk groups.
- the cancer is selected from the group comprising breast cancer, and lung cancer.
- Subject matter of the invention is further an assay for determining Pro-Enkephalin and Pro- Enkephalin fragments in a sample comprising two binders that bind to two different regions within the region of Pro-Enkephalin that is aminoacid 133-140 (LKELLETG, SEQ ID NO. 22) and aminoacid 152-159 (SDNEEEVS, SEQ ID NO. 23) wherein each of said regions comprises at least 4 or 5 amino acids.
- the assay sensitivity of said assay is able to quantify the Pro-Enkephalin or Pro-Enkephalin fragments of healthy subjects and is ⁇ 15pmol/, preferably ⁇ 10 pmol/1 and more preferably L ⁇ 6pmol/L.
- said binder exhibits an binding affinity to its binding partner of at least 10 7 M "1 , preferred 10 s M "1 , preferred affinity constant is lower than 10 9 most preferred lower than 10 ] 0 M "1 .
- a person skilled [ ⁇ ] in the art knows that it may be considered to compensate lower affinity by applying a higher dose of compounds and this measure would not lead out-of-the-scope of the invention binding affinity may be determined as described above.
- such assay is a sandwich assay, preferably a fully automated assay. It may be an ELISA fully automated or manual. It may be a so-called POC-test (point -of-care).
- Examples of automated or fully automated assay comprise assays that may be used for one of the following systems: Roche Elecsys®, Abbott Architect®, Siemens Centauer®, Brahms ryptor®, Biomerieux Vidas®, Alere Triage®. Examples of test formats are provided above.
- At least one of said two binders is labeled in order to be detected. Examples of labels are provided above.
- At least one of said two binders is bound to a solid phase.
- solid phases are provided above.
- said label is selected from the group comprising chemiluminescent label, enzyme label, fluorescence label, radioiodine label.
- a further subject of the present invention is a kit comprising an assay according to the present invention wherein the components of said assay may be comprised in one or more container.
- Peptides for immunization were synthesized (JPT Technologies, Berlin, Germany) with an additional N-terminal Cystein residue for conjugation of the peptides to bovine serum albumin (BSA).
- BSA bovine serum albumin
- the peptides were covalently linked to BSA by using Sulfo-SMCC (Perbio-science, Bonn, Germany). The coupling procedure was performed according to the manual of Perbio. Table 1 :
- the antibodies were generated according to the following method: A BALB/c mouse was immunized with 100 ⁇ g peptide-BSA-conjugate at day 0 and 14 (emulsified in 100 ⁇ complete Freund's adjuvant) and 50 pg at day 21 and 28 (in 100 ⁇ incomplete Freund's adjuvant). Three days before the fusion experiment was performed, the animal received 50 ⁇ g of the conjugate dissolved in 100 ⁇ saline, given as one intraperitonal and one intravenous injection.
- Spenocytes from the immunized mouse and cells of the myeloma cell line SP2/0 were fused with 1 ml 50 % polyethylene glycol for 30 s at 37 °C. After washing, the cells were seeded in 96- well cell culture plates. Hybrid clones were selected by growing in HAT medium [RPMI 1640 culture medium supplemented with 20 % fetal calf serum and HAT-supplement]. After two weeks the HAT medium is replaced with HT Medium for three passages followed by returning to the normal cell culture medium. The cell culture superaatants were primary screened for antigen specific IgG antibodies three weeks after fusion. The positive tested microcultures were transferred into 24-well plates for propagation. After retesting the selected cultures were cloned and recloned using the limiting- dilution technique and the isotypes were determined.
- Monoclonal antibody production Antibodies were produced via standard antibody production methods (Marx et al., Monoclonal Antibody Production (1997), ATLA 25, 121) and purified via Protein A-chromatography. The antibody purities were > 95 % based on SDS gel electrophoresis analysis.
- Labelled compound (tracer) 100 ⁇ g (100 ⁇ ) antibody (1 mg/ml in PBS, pH 7.4, was mixed with 10 ⁇ Acridinium NHS-ester (1 mg/ml in acetonitrile, inVent GmbH, Germany) (EP 0353971) and incubated for 20 min at room temperature. Labelled antibody was purified by gel-filtration HPLC on Bio-Sil SEC 400-5 (Bio-Rad Laboratories, Inc., USA) The purified labelled antibody was diluted in (300 mmol/1 potassiumphosphate, 100 mmol/1 NaCl, 10 mmol/1 Na-EDTA, 5 g/1 bovine serum albumin, pH 7.0). The final concentration was approx.
- RLU relative light units
- Solid phase antibody (coated antibody):
- Solid phase Polystyrene tubes (Greiner Bio-One International AG, Austria) were coated (18 h at room temperature) with antibody (1.5 ig antibody/0.3 ml 100 mmol/1 NaCl, 50 mmol/1 Tris/HCl, pH 7.8). After blocking with 5 % bovine serum albumine, the tubes were washed with PBS, pH 7.4 and vacuum dried.
- Antibody cross -reactivities were determined as follows: lug peptide in 300 ⁇ PBS, pH 7,4 was pipetted into Polystyrene tubes and incubated for lh at room temperature. After incubation the tubes were washed 5 times (each 1ml) using 5% BSA in PBS, pH 7,4. Each of the labelled antibodies were added (300 ⁇ in PBS, pH 7.4, 800.000 RLU/ 300 ⁇ ) an incubated for 2h at room temperature, After washing 5 times (each 1ml of washing solution (20 mmol/1 PBS, pH 7.4, 0.1 % Triton X 100), the remaining luminescence (labelled antibody) was quantified using the AutoLumat LB 953. MRPENK-peptide was used as reference substance (100%).
- MR-MRPENK antibody was used as coated tube antibody and CT-MRPENK antibody was used as labelled antibody.
- the assay was calibrated, using dilutions of synthetic MRPENK, diluted in 20 mM K2P04, 6 mM EDTA, 0,5% BSA, 50 ⁇ Amastatin, ⁇ Leupeptin, pH 8.0.
- Pro-Enkephalin control plasma is available at lCI-diagnostics, Berlin, Germany.
- Figure 1 shows a typical Pro-Enkephalin dose/ signal curve. Standard curve Pro-Enkephalin.
- the assay sensitivity was 20 determinations of 0-calibrator (no addition of MRPENK) + 2SD) 5,5 pmol/L.
- the mean value was 47,2 pmol/L, standard deviation ⁇ 1.2 pmol/L.
- the x axis is the Logarithmus Naturalis (LN) of the PENK concentration. All results were within the measurement of the assay, the lowest PENK concentration was 9 pmol/L. These results indicating the suitability of the used assay (assay sensitivity 5.5 pmol/L).
- HDL_B 044 ,252 ,031 1 .aeo 1 ,045 ,638 1 ,71
- FIG. 3 Kaplan Meier graphs, illustrating the cumulative breast cancer diagnosis in women Quartile (Q) 1 (below 40.4 pmol/1) quartile 2 (40.4-47.1 pmol/1), quartile 3 (47.2-54.1 pmoi/1), quartile 4 (above 54.1 pmol/1). Decreased PENK. indicates a long term increased risk of breast cancer development. Since any women with cancer history at day of baseline (blood sampling) were excluded, Pro-Enkephalin is highly predictive for future breast cancer development. Over all, women from Q 1 have a 3.6 times higher risk to develop breast cancer than women from Q 4.
- Antibodies were generated as described above.
- the antibody for labelling (LA) was generated 20 against P-NT 1-19 (H-CSDSEEEMKALEADFLTNMH (SEQ ID NO: 24)) and the solid phase antibody (SPA) was generated against peptide P-NT 44-62 (CNLNSPAEETGEVHEEELVA (SEQ ID NO: 25)).
- the technology used was a sandwich coated tube luminescence immunoassay, based on Acridinium ester labelling.
- Labelled compound (tracer) 100 ⁇ g (100 ⁇ ) LA (1 mg ml in PBS, pH 7.4, was mixed with 10 ⁇ Acridinium NHS-ester (1 mg/ml in acetonitrile, InVent GmbH, Germany) (EP 0353971) and incubated for 20 min at room temperature.
- Labelled LA was purified by gel-filtration HPLC on Bio-Sil SEC 400-5 (Bio-Rad Laboratories, Inc., USA) The purified LA was diluted in (300 mmol/l potassiumphosphate, 100 mmol/1 NaCl, 10 mmol/1 Na-EDTA, 5 g/1 bovine serum albumin, pH 7.0). The final concentration was approx. 800.000 relative light units (RLU) of labelled compound (approx. 20 ng labeled antibody) per 200 ⁇ . Acridiniumester chemiluminescence was measured by using an AutoLumat LB 953 (Berthold Technologies GmbH & Co. KG).
- Solid phase Polystyrene tubes (Greiner Bio-One International AG, Austria) were coated (18 h at room temperature) with SPA (1.5 ⁇ g SPA/0.3 ml 100 mmol/1 NaCl, 50 mmol/1 Tris/HCl, pH 7.8). After blocking with 5 % bovine serum albumine, the tubes were washed with PBS, pH 7.4 and vakuum dried.
- the assay was calibrated, using dilutions of Pro-Neurotensin containing human serum.
- a pool of human sera with high Pro-Neurotensin immunoreactivity (InVent Diagostika, Hennigsdorf, Germany) was diluted with horse serum (Biochrom AG, Germany) (assay standards).
- the standards were calibrated by use of the human Pro-Neurotensin-calibrator (ICI-Diagnostics, Berlin, Germany).
- the assay may be calibrated by synthetic or recombinant P-NT 1-11.7 or fragments thereof (see also Ernst et al., 2006).
- Table 8 combined analysis of PNT and PENK for breast cancer prediction.
- Table 9 combined analysis of PNT and PENK for breast cancer prediction.
- Fig. 4 Illustration example of combined analysis of Pro-Enkephalin for breast cancer prediction: We combined the women with lowest Pro-Enkephalin (1 st ) quartile and highest (4 th ) Pro- Neurotensin quartile (group 3). Within that high risk group about 19,02% of women developed breast cancer within the following 15 years.
- Group 2 is a combination of women with 3" d quartile of Pro-Neurotensin and 2 nd quartile of Pro- Enkephalin plus 2 nd quartile of Pro-Neurotensin and 3th quartile of Pro-Enkephalin. Within that medium risk group about 7,48% of women developed breast cancer within the following 15 years.
- Group 1 is a combination of women with 1 st quartile of Pro-Neurotensin and 4 th quartile of Pro- Enkephalin. Within that low risk group about 3,08 % of women developed breast cancer within the following 15 years.
- the Hazard risk between group 1 and group 3 is about 6,17.
- Lung cancer Pro-Enkephalin also predicts lung cancer in females.
- Pro-Enkephalin is not different in smoking and not smoking women p-0.44). As expected, smoking is a strong risk prediction marker for lung cancer (p ⁇ 0.0001). Surprisingly, although smoking is part of the equation, low Pro-Enkephalin indicated a 3.2 fold risk of developing lung cancer (table 10 a and 10 b).
- Figure 1 shows a typical Pro-Enkephalin dose/ signal curve. Standard curve Pro-Enkephalin.
- Figure 2 frequence distribution of Pro-Enkephalin in the females population:
- FIG. 3 Kaplan Meier graphs, illustrating the cumulative breast cancer diagnosis in women quartile (Q) 1 (below 40.4 pmol/1) quartile 2 (40.4-47.1 pmol/1), quartile 3 (47.2-54.1 pmol/1), quaitile 4 (above 54.1 pmol/1).
- Q quartile
- quartile 2 40.4-47.1 pmol/1
- quartile 3 47.2-54.1 pmol/1
- quaitile 4 above 54.1 pmol/1).
- Decreased PENK indicates a long term increased risk of breast cancer development. Since any women with cancer history at day of baseline (blood sampling) were excluded, Pro-Enkephalin is highly predictive for future breast cancer development. Over all, women from Q 1 have a 3.6 times higher risk to develop breast cancer than women from Q 4.
- Figure 4 Illustration example of combined analysis of Pro-Enkephalin for breast cancer prediction:
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES13779755.1T ES2676737T3 (en) | 2012-10-02 | 2013-10-01 | Method to predict the risk of getting cancer or to diagnose cancer in a female subject |
EP13779755.1A EP2904398B1 (en) | 2012-10-02 | 2013-10-01 | A method for predicting the risk of getting cancer in a female subject |
CN201380051613.1A CN104781672B (en) | 2012-10-02 | 2013-10-01 | Prediction female subject cancer stricken risk or the method for diagnosing its cancer |
JP2015534992A JP6392762B2 (en) | 2012-10-02 | 2013-10-01 | Methods to help predict the risk of developing cancer in female subjects |
PL13779755T PL2904398T3 (en) | 2012-10-02 | 2013-10-01 | A method for predicting the risk of getting cancer in a female subject |
DK13779755.1T DK2904398T3 (en) | 2012-10-02 | 2013-10-01 | Procedures for predicting the risk of getting cancer in a female individual |
RU2015116675A RU2671578C2 (en) | 2012-10-02 | 2013-10-01 | Method for predicting risk of getting cancer or diagnosing cancer in female subject |
CA2886814A CA2886814C (en) | 2012-10-02 | 2013-10-01 | A method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
US14/432,808 US9702876B2 (en) | 2012-10-02 | 2013-10-01 | Method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
HK16100382.8A HK1212762A1 (en) | 2012-10-02 | 2016-01-14 | A method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
US15/641,436 US20170307618A1 (en) | 2012-10-02 | 2017-07-05 | Method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
US17/955,765 US20230147663A1 (en) | 2012-10-02 | 2022-09-29 | Method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12187050 | 2012-10-02 | ||
EP12187050.5 | 2012-10-02 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/432,808 A-371-Of-International US9702876B2 (en) | 2012-10-02 | 2013-10-01 | Method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
US15/641,436 Continuation US20170307618A1 (en) | 2012-10-02 | 2017-07-05 | Method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014053502A1 true WO2014053502A1 (en) | 2014-04-10 |
Family
ID=46940411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/070471 WO2014053502A1 (en) | 2012-10-02 | 2013-10-01 | A method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
Country Status (12)
Country | Link |
---|---|
US (3) | US9702876B2 (en) |
EP (1) | EP2904398B1 (en) |
JP (1) | JP6392762B2 (en) |
CN (2) | CN110221071A (en) |
CA (1) | CA2886814C (en) |
DK (1) | DK2904398T3 (en) |
ES (1) | ES2676737T3 (en) |
HK (1) | HK1212762A1 (en) |
PL (1) | PL2904398T3 (en) |
RU (3) | RU2671578C2 (en) |
TR (1) | TR201809183T4 (en) |
WO (1) | WO2014053502A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
CN107430135A (en) * | 2015-02-27 | 2017-12-01 | 思芬构技术有限公司 | A kind of method for the risk of obesity for predicting subject |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6317763B2 (en) * | 2013-01-08 | 2018-04-25 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method for predicting or diagnosing cancer risk in a subject |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0353971A2 (en) | 1988-08-01 | 1990-02-07 | Ciba Corning Diagnostics Corp. | Acridinium esters and method for detection of an analyte using acridinium esters and liposomes |
US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
US20080160557A1 (en) * | 2006-09-28 | 2008-07-03 | Cady Roger K | Diagnostic Test for Head and Facial Pain |
EP2293079A2 (en) * | 2004-05-13 | 2011-03-09 | B.R.A.H.M.S GmbH | Use of precursors of enkephalins and/or their fragments in medical diagnostics |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
DE60235416D1 (en) * | 2001-05-04 | 2010-04-01 | Biosite Inc | Diagnostic markers of acute coronary syndromes and their uses |
JP2008529495A (en) * | 2005-02-04 | 2008-08-07 | グラクソ グループ リミテッド | Optimization of heterologous polypeptide expression |
JPWO2009044561A1 (en) * | 2007-10-03 | 2011-02-03 | 静岡県 | Anti-proNT / NMN monoclonal antibody |
ES2538002T3 (en) * | 2009-01-07 | 2015-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treatment, prognostic evaluation and breast cancer detection |
EP2233590A1 (en) * | 2009-01-28 | 2010-09-29 | AIT Austrian Institute of Technology GmbH | Methylation assay |
DK2427764T3 (en) * | 2009-05-05 | 2017-09-11 | Brahms Gmbh | VASOACTIVE HORMON-BASED STRATIFICATION OF PATIENTS SUFFERING OF DISEASES RELATED TO ENDOTELIAL FUNCTION / DYSFUNCTION |
MX2011012913A (en) * | 2009-06-01 | 2012-02-21 | Genetic Technologies Ltd | Methods for breast cancer risk assessment. |
CA2771154A1 (en) * | 2009-08-14 | 2011-02-17 | Allergan, Inc. | Methods of treating cancer using opioid retargeted endpeptidases |
-
2013
- 2013-10-01 RU RU2015116675A patent/RU2671578C2/en active
- 2013-10-01 RU RU2018138055A patent/RU2707755C2/en active
- 2013-10-01 ES ES13779755.1T patent/ES2676737T3/en active Active
- 2013-10-01 TR TR2018/09183T patent/TR201809183T4/en unknown
- 2013-10-01 CN CN201910496671.4A patent/CN110221071A/en active Pending
- 2013-10-01 CN CN201380051613.1A patent/CN104781672B/en active Active
- 2013-10-01 CA CA2886814A patent/CA2886814C/en active Active
- 2013-10-01 WO PCT/EP2013/070471 patent/WO2014053502A1/en active Application Filing
- 2013-10-01 PL PL13779755T patent/PL2904398T3/en unknown
- 2013-10-01 EP EP13779755.1A patent/EP2904398B1/en active Active
- 2013-10-01 US US14/432,808 patent/US9702876B2/en active Active
- 2013-10-01 DK DK13779755.1T patent/DK2904398T3/en active
- 2013-10-01 JP JP2015534992A patent/JP6392762B2/en active Active
-
2016
- 2016-01-14 HK HK16100382.8A patent/HK1212762A1/en unknown
-
2017
- 2017-07-05 US US15/641,436 patent/US20170307618A1/en active Pending
-
2019
- 2019-11-22 RU RU2019137669A patent/RU2019137669A/en unknown
-
2022
- 2022-09-29 US US17/955,765 patent/US20230147663A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0353971A2 (en) | 1988-08-01 | 1990-02-07 | Ciba Corning Diagnostics Corp. | Acridinium esters and method for detection of an analyte using acridinium esters and liposomes |
US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
EP2293079A2 (en) * | 2004-05-13 | 2011-03-09 | B.R.A.H.M.S GmbH | Use of precursors of enkephalins and/or their fragments in medical diagnostics |
US20080160557A1 (en) * | 2006-09-28 | 2008-07-03 | Cady Roger K | Diagnostic Test for Head and Facial Pain |
Non-Patent Citations (8)
Title |
---|
BELTING ET AL., CANCER EPIDEMIOL BIOMARKERS PREV, 2012, pages 1 - 10 |
ERNST ET AL., PEPTIDES, 2006, pages 1787 - 1793 |
J. F. DORGAN ET AL: "Prospective Case-Control Study of Serum Mullerian Inhibiting Substance and Breast Cancer Risk", JNCI JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 101, no. 21, 9 October 2009 (2009-10-09), pages 1501 - 1509, XP055052900, ISSN: 0027-8874, DOI: 10.1093/jnci/djp331 * |
LANE, R.D.: "A short-duration polyethylene glycol fusiontechnique for increasing production of monoclonal antibody-secreting hybridomas", J. IMMUNOL. METH., vol. 81, 1985, pages 223 - 228 |
LINNOILA R I ET AL: "Decreased expression of neuropeptides in malignant paragangliomas: An immunohistochemical study", HUMAN PATHOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 19, no. 1, 1 January 1988 (1988-01-01), pages 41 - 50, XP026443064, ISSN: 0046-8177, [retrieved on 19880101] * |
MARX ET AL., MONOCLONAL ANTIBODY PRODUCTION, 1997, pages 121 |
SMITH J P ET AL: "Methionine enkephalin: A new tumor marker for pancreatic cancer?", PANCREAS, RAVEN PRESS, NEW YORK, NY, US, vol. 15, no. 4, 1 November 1997 (1997-11-01), pages 456, XP008160009, ISSN: 0885-3177 * |
ZIEGLER, B. ET AL.: "Glutamate decarboxylase (GAD) is not detectable on the surface of rat islet cells examined by cytofluorometry and complement-dependent antibody-mediated cytotoxicity of monoclonal GAD antibodies", HORM. METAB. RES., vol. 28, 1996, pages 11 - 15 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
US20160097781A1 (en) * | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
CN107430135A (en) * | 2015-02-27 | 2017-12-01 | 思芬构技术有限公司 | A kind of method for the risk of obesity for predicting subject |
Also Published As
Publication number | Publication date |
---|---|
RU2015116675A (en) | 2016-11-27 |
RU2018138055A (en) | 2018-11-14 |
TR201809183T4 (en) | 2018-07-23 |
RU2018138055A3 (en) | 2019-06-10 |
EP2904398A1 (en) | 2015-08-12 |
RU2019137669A (en) | 2021-05-24 |
PL2904398T3 (en) | 2018-11-30 |
CA2886814A1 (en) | 2014-04-10 |
CN104781672A (en) | 2015-07-15 |
CA2886814C (en) | 2021-09-07 |
RU2707755C2 (en) | 2019-11-29 |
EP2904398B1 (en) | 2018-04-11 |
CN110221071A (en) | 2019-09-10 |
ES2676737T3 (en) | 2018-07-24 |
RU2019137669A3 (en) | 2021-05-24 |
HK1212762A1 (en) | 2016-06-17 |
US20150268240A1 (en) | 2015-09-24 |
JP6392762B2 (en) | 2018-09-19 |
JP2015532423A (en) | 2015-11-09 |
CN104781672B (en) | 2019-07-05 |
US20170307618A1 (en) | 2017-10-26 |
US20230147663A1 (en) | 2023-05-11 |
US9702876B2 (en) | 2017-07-11 |
RU2671578C2 (en) | 2018-11-02 |
DK2904398T3 (en) | 2018-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230147663A1 (en) | Method for predicting the risk of getting cancer or diagnosing cancer in a female subject | |
US20210333292A1 (en) | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction | |
US20210109102A1 (en) | Method for predicting the risk of getting cancer or diagnosing cancer in a female subject | |
US20200326350A1 (en) | Method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject | |
RU2652304C2 (en) | Method for predicting risk of getting cardiovascular event in female subject | |
EA034364B1 (en) | Immunoassay for the detection of chromogranin a | |
US10605812B2 (en) | Method for predicting the risk of getting cancer or diagnosing cancer in a subject |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13779755 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2886814 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015534992 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14432808 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013779755 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015116675 Country of ref document: RU Kind code of ref document: A |